Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

NICE overturns negative Glivec guidance

Recommends drug for reimbursement in GIST four years after rejection

- PMLiVE

Novartis brings creative malaria campaign to Pinterest

Invites users to create their own mosquito-killing story

- PMLiVE

NICE set to back Alexion’s costly ‘ultra-orphan’ drug

Final draft guidance recommends aHUS treatment Soliris

- PMLiVE

NICE backs drug to cut alcohol consumption

Final guidance for Lundbeck’s Selincro for use on NHS in England

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Novartis partners with NHS on eye service

Launches community programme in Bristol

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

Novartis gets EU nod for rare disease drug Signifor

Long-acting formulation of drug approved for growth disorder acromegaly

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

NICE wants more evidence on skin damage technologies

But ‘spray-on-skin’ and clothes to prevent ulcers can still be used on NHS

Novartis building

Novartis to deliver three million malaria treatments in Zambia

Part of Malaria No More’s Power of One campaign

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links